Q-omics provides the consensus-scored MAGOH2P profile across patient tissues and cancer cell-line models. MAGOH2P expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MAGOH2P is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, MAGOH2P RNA expression shows 19,946 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, THCA, and THYM as cancer lineages where MAGOH2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAGOH2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAGOH2P survival associations across molecular data types. MAGOH2P RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAGOH2P RNA expression–survival associations across cancer types. High MAGOH2P expression shows unfavorable associations in LGG, but favorable associations in HNSC, UCS, BRCA, READ and OV. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MAGOH2P RNA expression.
This table summarizes MAGOH2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MAGOH2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAGOH2P shows lower tumor expression in THCA, KICH, COAD, BLCA, LUAD and LUSC. The THCA box plot shows higher MAGOH2P RNA expression in normal versus tumor tissue (log2 FC = −1.591, t-test p < 0.001).
This table shows molecular features associated with MAGOH2P in patient tissues and cancer cell lines. In patient samples, MAGOH2P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAGOH2P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
